TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Mental Stress Reduction in Defibrillator Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>21 years,~* ICD Implantation,~* \> 3 months following ICD implantation,~* willingness to give informed consent~Exclusion Criteria:~* Episodes within prior 3 months of: acute coronary syndrome, myocardial infraction, Coronary Artery By-pass Graft surgery, percutaneous coronary intervention, hospital admission any cause,~* severe mental illness,~* life expectancy \< 1 year,~* hyperkalemia,~* hypokalemia,~* hypomagnesemia,~* hypermagnesemia,~* unwillingness to give informed consent

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Cognitive Behavioral Stress Management (Type: ACTIVE_COMPARATOR): 10 week program of Cognitive Behavioral Stress Management (CBSM) group sessions
- Patient Education (Type: ACTIVE_COMPARATOR): 10 week program of once weekly Patient Education group sessions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of mantle cell lymphoma~* Stable disease after first- or second-line chemotherapy~* No uncontrolled cerebral or leptomeningeal disease~PATIENT CHARACTERISTICS:~* WHO performance status 0-2~* Life expectancy ≥ 3 months~* Age ≥ 60 years or patients ≥ 40 and \< 60 years who are not suitable for high-dose chemotherapy followed by autologous stem cell transplantation or allogeneic stem cell transplantation~* ANC ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin \> 9 g/dL~* Serum creatinine ≤ 1.5 times upper limit of normal (ULN)~* SGPT and SGOT ≤ 3 times ULN~* Bilirubin ≤ 1.5 times ULN~* No other malignancies within the past 3 years except treated cervical carcinoma or basal cell cancer~* No other serious or non-controlled illnesses (e.g., diabetes mellitus, uncontrolled hypertension, serious infections, serious malnutrition, unstable angina pectoris, weak heart, myocardial infarction within the past 6 months, chronic liver illness, active ulceration in the gastrointestinal tract, psychiatric illness)~* No known HIV infection~* No gastrointestinal disturbances that could influence the absorption of everolimus and cause short-intestine syndrome (e.g., atrophic gastritis)~* No coagulation or bleeding diatheses~* Not pregnant or nursing~* Fertile patients must use effective contraception~* Patients must have complied with their previous drug prescription~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* See Patient Characteristics~* Recovered from all prior therapy~* At least 2 weeks since prior surgery, radiotherapy, or systemic antitumor therapy~* More than 4 weeks since prior experimental medication~* No chronic therapy with systemic steroids or other immunosuppressants except rituximab~* No prior organ transplantation~* No therapy with vitamin K antagonist, except low-dose coumarin~* No prior mTOR inhibitors

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Oral TXA in Reducing Blood Loss and Transfusion in Hip Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients presenting with femoral neck, intertrochanteric and subtrochanteric femur fractures Patients age 18 and older Low energy injury~Exclusion Criteria:~Pregnant or breast-feeding women Allergy to tranexamic acid Acquired disturbances of color vision Thrombophilia Antithrombin deficiency Factor V Leiden Antiphospholipid Syndrome Protein C and S deficiency History of heparin induced thrombocytopenia Sickle cell anemia Myeloproliferative disorders International Normalized Ratio (INR) \> 1.4 Partial Thromboplastin Time (PTT) \> 1.4 times normal A history of arterial or venous thromboembolism Cerebral Vascular Accident Deep Vein Thrombosis Pulmonary Embolism Subarachnoid hemorrhage Active intravascular clotting Participation in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tranexamic acid (Type: EXPERIMENTAL): Study subjects randomized to receive the TXA group will receive 3 oral capsules of 650 mg each of TXA for a total of 1.95 g. One dose will be given upon diagnosis of a hip fracture in the emergency department (ED) and a second dose will be given two hours prior to surgical incision.
- Placebo (Type: PLACEBO_COMPARATOR): Study subjects randomized to the placebo group will receive an equivalent dose of cellulose in 3 oral capsules. One dose will be given upon diagnosis of a hip fracture in the ED and a second dose will be given two hours prior to surgical incision.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pessary Versus Cerclage With or Without Progesterone in Twins

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Women with a twin pregnancy (mono- and di-chorionic)~* 16 0/7 to 22 0/7 weeks of gestation~* Maternal age ≥18 yrs~* Cervical length ≤28 mm~* Informed consent~* Not participating in another preterm birth study at the same time~Exclusion Criteria:~* Uterine anomalies~* Cervical dilation with visible amniotic membranes or amniotic membranes prolapsed into the vagina~* Twin-to-twin transfusion syndrome~* Stillbirth or major congenital abnormalities in any of the fetus~* Severe vaginal discharge~* Acute vaginitis or cervicitis~* Vaginal bleeding~* Placental preavia~* Vasa preavia~* Premature rupture of membranes~* Premature labor with/without ruptured membrane~* Suspicion of chorioamnionitis~* Cerclage or pessary in place or unable to undergo cervical cerclage or pessary

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pessary group (Type: ACTIVE_COMPARATOR): A soft, flexible, silicone pessary, purchased from the manufacturer (Arabin®, Dr Arabin GmbH \& Co KG, Germany) will be inserted through the vagina, upward around the cervix by 4 senior clinicians, who had experienced with pessary used, within one week of randomisation. Size of the pessary will be determined at the time of speculum inspection.
- Cerclage group (Type: ACTIVE_COMPARATOR): Women will be receiving the cervical cerclage according to local protocol, within a week after randomisation. 3 senior clinicians who had experienced with cerclage, will perform cerclage, using Mc Donald technique, under spinal anaesthesia.
- Pessary plus progesterone group (Type: ACTIVE_COMPARATOR): 400 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 400mg, Actavis, United Kingdom), will be applied once daily at bedtime, starting from the day of randomisation, in addition to the pessary that has been placed. Participants will be asked to record their drug application in a patient diary sheet for up to 140 days.
- Cerclage plus progesterone group (Type: ACTIVE_COMPARATOR): 400 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 400mg, Actavis, United Kingdom), will be applied once daily at bedtime, starting from the day of randomisation, in addition to the cerclage that has been placed. Participants will be asked to record their drug application in a patient diary sheet for up to 140 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The subject must have:~* completed the 6-month treatment in the main study~* agreed to continue to use only the analgesic rescue medication permitted by the protocol during the Treatment and Follow-up Periods~* agreed to continue to comply with the requirements of the study protocol for the duration of the extension study~Exclusion Criteria:~The subject will be excluded if she:~* is pregnant or breast feeding or is planning a pregnancy within the duration of the of the study (including the Follow-up Period)~* likely to require treatment during the study with any of the restricted medications~* has any other clinically significant gynecologic condition identified during the main study on transvaginal ultrasound (TVUS), on endometrial biopsy or at the manual breast examination, which might interfere with the study efficacy and safety objectives~* meets any of the main study discontinuation criteria

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Linzagolix 75 mg (Type: EXPERIMENTAL): None
- Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Perineural Clonidine as an Adjuvant With Ropivacaine for Popliteal Nerve Block in Patients Undergoing Foot and Ankle Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient undergoing foot or ankle surgery with popliteal nerve block planned for postoperative analgesia.~2. Adult, 19 years of age and older.~3. Subject classified as American Society of Anesthesiology (ASA) class 1, 2, or 3. The ASA defines these statuses as follows: 1-A normal healthy patient. 2-A patient with mild systemic disease. 3-A patient with severe systemic disease.~   -~Exclusion Criteria:~1. Any subject not classified as an ASA 1, 2, or 3.~2. Allergy/intolerance to local anesthetic, clonidine, and/or oxycodone.~3. Subject with a history of continuous opioid use for greater than one month prior to surgery.~4. Pre-existing neurologic deficit in lower extremity (surgical site).~5. Clinically significant coagulopathy (hemophilia, von Willebrand disease).~6. Patients who fail to follow the UAB Department of Anesthesiology Algorithm for the Preoperative Management of an Angiotensin Converting Enzyme Inhibitor (ACEI) or an Angiotensin Receptor Blocker (ARB). A copy of the algorithm can be found in Appendix 1. -

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clonidine and Ropivacaine (Type: EXPERIMENTAL): A bolus of 20 mL of 0.5% ropivacaine mixed with clonidine 1mcg/kg will be injected through the stimulating needle with gentle aspiration between divided doses (5 mL per dose).
- Ropivacaine (Type: ACTIVE_COMPARATOR): Standard saphenous nerve block (adductor canal approach) will be performed using 15ml of 0.5% ropivacaine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound and Endometrial Hyperplasia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal obese subjects, who have diabetes or a prediabetic state, or hypertension~Exclusion Criteria:~* Women who have had a hysterectomy

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Ultrasound and Biopsy (Type: EXPERIMENTAL): Transvaginal Ultrasound and Endometrial Biopsy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Manidipine Versus Amlodipine in Patients With Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients between the ages of 20 and 80 years with uncomplicated essential hypertension are eligible.~* Inclusion criteria requires that patients have either stage I or stage II hypertension (mean sitting systolic Blood Pressure (BP) 140-179 mmHg, diastolic BP 90-109 mmHg).~* The patients are newly diagnosed or known hypertensive subjects who were not taking antihypertensive agents for more than the last 4 weeks.~Exclusion Criteria:~* Patients are excluded from the study if they have any evidence of clinically significant concurrent medical conditions including cardiac, renal, hepatic, gastrointestinal, or endocrinologic disease.~* Patients are also excluded if they have known hypersensitivity or serious drug reactions to Calcium Channel Blockers (CCBs), any evidence of prior deep vein thrombosis, lymphatic disease, or concurrent requirement for medications that could affect Blood Pressure (BP) or salt and water retention (e.g, nonsteroidal antinflammatory drugs, estrogen containing drugs).

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Manidipine 20mg (Type: EXPERIMENTAL): 50 patients will be administered orally manidipine 20mg/day after 1\~2 week run-in period
- Amlodipine 10mg (Type: ACTIVE_COMPARATOR): 50 patients will be administered orally amlodipine 10mg/day after 1\~2 week run-in period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Virtual Reality for the Education of Cancer Patients Undergoing Radiation Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to understand and the willingness to sign a written informed consent document~* All races and ethnic groups will be included~* Participants with any cancer diagnosis that is intended to receive RT for curative intent for their cancer~* Participants must have a minimum of 10 planned RT treatments~Exclusion Criteria:~* Any prior RT~* Known history of anxiety or depression~* Individuals with known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial~* Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of participant safety or study results~* Inability to understand either English or Spanish

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (VERT) (Type: EXPERIMENTAL): Patients complete a radiation therapist-led education module using virtual reality over 30 minutes at the first treatment appointment, prior to radiation therapy treatment.
- Arm II Control Group I (usual education materials) (Type: ACTIVE_COMPARATOR): Patients receive the usual verbal and written education materials at the first treatment appointment, prior to radiation therapy treatment.
- Arm II Control Group II (face-to-face education module) (Type: ACTIVE_COMPARATOR): Patients complete a radiation therapist-led face-to-face education module at the first treatment appointment, prior to radiation therapy treatment.
- Observational Cohort (usual education materials) (Type: ACTIVE_COMPARATOR): Observational patients receive the usual verbal and written education materials at the first treatment appointment, prior to radiation therapy treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Follow-Up Study of Patients Receiving ATL001

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have given written informed consent to participate in the study.~2. Patients must have received ATL001 in a previous Clinical Trial.~3. Patients must be considered, in the opinion of the Investigator, capable of complying with the protocol requirements.~Exclusion Criteria:~There are no exclusion criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental: ATL001 (Type: OTHER): Patients who have previously received ATL001 in a clinical trial will be evaluated in this trial for long-term safety and clinical activity.
- Patients who have previously received ATL001 in study ATX-NS-001 or study ATX-ME-001 (Type: OTHER): Patients who have previously received ATL001 in study ATX-NS-001 or study ATX-ME-001

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological diagnosis of ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer~  * Progressive or recurrent disease~* Received ≥ 1 prior course of chemotherapy~* Measurable or evaluable disease OR disease assessable by CA 125, defined as CA 125 \> normal that has increased over 2 readings \> 14 days apart~* Karnofsky performance status 10-50%~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Creatinine ≤ 1.5 mg/dL~* Alkaline phosphatase ≤ 3 times upper limit of normal (ULN)~* Total bilirubin ≤ 1.5 times ULN~* SGOT ≤ 3 times ULN~* Life expectancy ≥ 12 weeks~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use accepted and effective non-hormonal contraception~Exclusion Criteria:~* Other neoplasm within the past 5 years except for nonmetastatic, nonmelanoma skin cancers, carcinoma in situ of the cervix, or cancer cured by surgery or chemotherapy~* Septicemia, severe infection, or acute hepatitis~* Severe gastrointestinal bleeding, defined as requiring a blood transfusion or hospitalization

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Escalating Cohorts (Type: EXPERIMENTAL): Patients receive topotecan intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 6 patients will be treated at the MTD.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues